Mary Szela

Ms Szela is currently chief executive officer of TriSalus Life Sciences, a company focused on improving outcomes in patients with pancreatic and liver metastasis by combining immuno-oncology therapeutics with a novel technology to enable improved patient outcomes.

Prior to TriSalus, she held the position of CEO of Novelion Therapeutics where she success-fully resolved significant legal, regulatory and compliance issues facing the company; re-formulated the Board and entire leadership team and executed a merger with QLT to strengthen the balance sheet to ensure survival of the company.

Prior to her role at Novelion, Szela served as CEO of Melinta Pharmaceuticals, where she re-vitalized the company following a failed IPO. Under her leadership, she transformed Melinta from a scientific organization to one prepared for commercial launch of multiple antibiotic products with billion-dollar potential. Additionally, she secured $270 million of new capital for the company, accelerated the pipeline, revitalized the discovery platform, developed an innovative go-to-market strategy, rebuilt the management team, and prepared the company to access the public markets.

Previously, Szela spent 25 years of progressive P&L leadership roles at Abbott Laboratories, a top 10 diversified health care company. She held positions of senior leadership including president of U.S. pharmaceuticals, an $9 billion business, the primary profit driver of the company. During her Abbott tenure, she was consistently a catalyst for profound and productive change during a time of tremendous turmoil within the industry.

Ms Szela serves as a member of the boards of TriSalus Life Sciences, Coherus Biosciences, Inc, Kura Oncology, Alimera Biosciences, Omega Therapeutics, and Senda Biosciences.

Ms Szela has an M.B.A. from the University of Illinois at Chicago, US, and a B.S. Nursing degree from the University of Illinois at Chicago, US.